• Explore /
  • Poster
  • / Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).

Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).

Abstract Poster

Authors

Dean Bajorin

Dean F. Bajorin

Memorial Sloan Kettering Cancer Center, New York, NY

Dean F. Bajorin , Padmanee Sharma , David I. Quinn , Elizabeth R. Plimack , Jean H. Hoffman-Censits , Peter H. O'Donnell , Arlene O. Siefker-Radtke , Nadeem Anwar Sheikh , Jennifer Susan LIll , James B. Trager , Leonard G. Gomella

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Other GU Kidney and Bladder Cancer

Clinical Trial Registration Number

NCT01353222

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4513)

DOI

10.1200/JCO.2016.34.15_suppl.4513

Abstract #

4513

Poster Bd #

136

Abstract Disclosures

Similar Posters

First Author: Dean F. Bajorin

First Author: Dean F. Bajorin

First Author: Lawrence G. Lum

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Understanding the peripheral cellular immunome in patients with breast cancer.

Understanding the peripheral cellular immunome in patients with breast cancer.

First Author: Karenia Landa